Program
Autologous Tumor Infiltrating Lymphocytes GT201
Also written as “GT201”, “Autologous tumor infiltrating lymphocyte injection(GT201)” and “GT201 injection”.
Its studies are mostly in Lung Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.
Drug pageAutologous Tumor Infiltrating Lymphocytes GT201: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grit Biotechnologyits history only | 82 open or running | phase 2since Feb 6, 2023 | Jun 4, 2022 | Apr 30, 2027NCT06190275 |
| Gritbio Medicineits history only | 11 open or running | phase 2since Jul 27, 2026 | Jul 27, 2026 | Jun 2030phase 2 · NCT07766317 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 4, 2022First study: phase 1 study in Solid TumorNew to Grit BiotechnologyGrit Biotechnology · NCT05430360 · 2 enrolled · China
- Feb 6, 2023Phase 2 study in Solid TumorGrit Biotechnology · NCT05729399 · 6 enrolled · China
- Oct 20, 2023Phase 2 study in Advanced Solid TumorsGrit Biotechnology · NCT06144671 · 78 planned · China
- Dec 19, 20232 no phase studiesGrit Biotechnology · NCT06190275, NCT06191900
- Jan 23, 2024No phase study in Carcinoma, Non-Small-Cell LungGrit Biotechnology · NCT06235242 · 2 enrolled · China
- Jul 19, 2024No phase study in Lung NeoplasmsGrit Biotechnology · NCT06519669 · 2 enrolled · China
- Feb 5, 2025Early phase 1 study in Adult Gynecological TumorsGrit Biotechnology · NCT06834542 · 1 enrolled · China
- Jul 27, 2026Gritbio Medicine’s first study: phase 2 study in Advanced Solid Tumors CancerNew to Gritbio MedicineGritbio Medicine · NCT07766317 · 63 planned
Ahead
- Apr 30, 2027Primary completion: no phase study in Squamous Cell Carcinoma of Head and NeckGrit Biotechnology · NCT06190275
- Dec 30, 2027Primary completion: phase 2 study in Advanced Solid TumorsGrit Biotechnology · NCT06144671
- Jun 2030Primary completion: phase 2 study in Advanced Solid Tumors CancerGritbio Medicine · NCT07766317
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07766317Advanced Solid Tumors Cancer | 2 | Not yet recruiting | Gritbio Medicine | Jun 2030 | 63 |
| NCT06834542Adult Gynecological Tumors · China | Early 1 | Terminated | Grit Biotechnology | Dec 30, 2025 | 1 |
| NCT06519669Lung Neoplasms · China | – | Terminated | Grit Biotechnology | Dec 30, 2025 | 2 |
| NCT06235242Carcinoma, Non-Small-Cell Lung · China | – | Terminated | Grit Biotechnology | Dec 30, 2025 | 2 |
| NCT06191900Adult · China | – | Terminated | Grit Biotechnology | Dec 30, 2025 | 4 |
| NCT06190275Squamous Cell Carcinoma of Head and Neck · China | – | Recruiting | Grit Biotechnology | Apr 30, 2027 | 32 |
| NCT06144671Advanced Solid Tumors · China | 2 | Recruiting | Grit Biotechnology | Dec 30, 2027 | 78 |
| NCT05729399Solid Tumor · China | 2 | Terminated | Grit Biotechnology | Dec 30, 2025 | 6 |
| NCT05430360Solid Tumor · China | 1 | Terminated | Grit Biotechnology | Dec 30, 2025 | 2 |
How it is read
Names in the registry
- “GT201”, 4 entries
- “Autologous tumor infiltrating lymphocyte injection(GT201)”, 2 entries
- “GT201 injection”, 1 entry
- “GT201 injection in combination with teraplizumab injection”, 1 entry
- “GT201 in combination with PD-1 inhibitors”, 1 entry
Codes read as this program: GT201.
Conditions, from the studies’ own filings
- Lung Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.